INFI - Infinity Pharma gains on encouraging eganelisib + nivolumab data in urothelial cancer trial

Infinity Pharmaceuticals (INFI) rises 22% premarket following data from Phase 2 MARIO-275 (MAcrophage Reprogramming in Immune Oncology) study, evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo) in platinum-refractory, I/O naïve patients with advanced urothelial cancer ((UC)).The objective of the study was to address the need for better treatments for second line (2L) advanced UC patients. In the overall population, the combination of eganelisib with nivolumab demonstrated an increase over nivolumab monotherapy in:Overall response rate ((ORR)) (30% vs. 25%);Disease control rate ((DCR)) (55% vs. 31%);Best responses of complete response ((CR)) (12% vs. 6%);Stable disease ((SD)) (24% vs. 6%).The addition of eganelisib on top of 2L standard of care nivolumab led to clear benefits for PD-L1 low patients, with an over 85% increase in ORR vs. the control arm.Combination of eganelisib with nivolumab demonstrated improved ORR, DCR, CR, SD and extended PFS with a hazard ratio of 0.54 reflecting 46% reduction

For further details see:

Infinity Pharma gains on encouraging eganelisib + nivolumab data in urothelial cancer trial